MET overexpression and amplification define a distinct molecular subgroup for targeted therapies in gastric cancer | Gastric Cancer
MET mutations identified following crizotinib treatment. (A–C) The... | Download Scientific Diagram
The clinical efficacy of combinatorial therapy of EGFR-TKI and crizotinib in overcoming MET amplification-mediated resistance fr
Emergence of MET hyper-amplification at progression to MET and BRAF inhibition in colorectal cancer | British Journal of Cancer
Cancers | Free Full-Text | Mechanisms of Acquired Resistance to ALK Inhibitors and the Rationale for Treating ALK-positive Lung Cancer
MET Inhibition in Non-Small Cell Lung Cancer - European Medical Journal
Cancers | Free Full-Text | The Development and Role of Capmatinib in the Treatment of MET-Dysregulated Non-Small Cell Lung Cancer—A Narrative Review
Responses to the multitargeted MET/ALK/ROS1 inhibitor crizotinib and co-occurring mutations in lung adenocarcinomas with MET amplification or MET exon 14 skipping mutation. | Semantic Scholar
MET Tyrosine Kinase Inhibitor Crizotinib (PF-02341066) Shows Differential Antitumor Effects in Non-small Cell Lung Cancer According to MET Alterations - ScienceDirect
Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration | Nature Medicine
Responses to the multitargeted MET/ALK/ROS1 inhibitor crizotinib and co-occurring mutations in lung adenocarcinomas with MET amplification or MET exon 14 skipping mutation - ScienceDirect
Crizotinib in Patients With MET-Amplified NSCLC - ScienceDirect
Présentation PowerPoint
Phase II, open-label, multicenter trial of crizotinib in Japanese patients with advanced non-small cell lung cancer harboring a MET gene alteration: Co-MET study | Trials | Full Text
Downregulation of MET in H1993 cells, effects of crizotinib on EGFR... | Download Scientific Diagram
Crizotinib Pathway, Pharmacokinetics/Pharmacodynamics
The role of MET in chemotherapy resistance | Oncogene
Table 1 from Amplification MET ( PF-02341066 ) in Gastric Cancer Positive for Antitumor Action of the MET Tyrosine Kinase Inhibitor Crizotinib | Semantic Scholar
Frontiers | Case Report: Sequential Combination Targeted Therapy With Type I and II MET Inhibitors in a Metastatic EGFR-Mutated, MET-Amplified NSCLC Patient With Acquired MET Y1230H Mutation
EGFR/MET-driven tumors are sensitive to the osimertinib and crizotinib... | Download Scientific Diagram
IJMS | Free Full-Text | Targeting MET in Non-Small Cell Lung Cancer (NSCLC): A New Old Story?
Crizotinib inhibits activation of MET pathway caused by MET extracellular SEMA domain duplication - ScienceDirect
Cancers | Free Full-Text | Overview of Molecular Detection Technologies for MET in Lung Cancer
